Implementing DSCSA: Stabilization Period and Expectations

Published 2023-11-03

Download video MP4 360p

Recommendations

40:13

Pharmaceutical Quality Symposium 2023: Quality, Supply Chain & Advanced Manufacturing – D1 – Part 1
56:21

FSMA Final Rule on Pre-Harvest Agricultural Water
7:42:03

REdI Annual Conference 2024: CBER (Biologics) Innovation in Medical Product Development (Day 2 of 2)
01:58

Quick Updates to Help Keep You Safe: Milk, Device Charging, & Sunscreen | FDA In Your Day Ep. 6
8:28:56

FDA-MHRA-HC 2024 Joint Symposium (Day 3)
1:12:24

Strategies to Increase Clinical Trial Participation for Diverse Communities: OMHHE REACH Consortium
7:00:43

185th Meeting of Vaccines and Related Biological Products Advisory Committee
01:00

Contact Lenses: Safe Use of Hydrogen Peroxide Solution #shorts
6:52:20

REdI Annual Conference 2024: CDRH (Devices) Innovation in Medical Product Development (Day 2 of 2)
05:27

10 More Facts about What FDA Does and Does Not Approve | #FDAFacts 11-20
1:31:19

4th Annual National Black Family Cancer Awareness, Engaging the Generations, #BlackFamCan
01:31

Contact Lenses: Safe Use of Hydrogen Peroxide Solution
05:28

Episode 5 - On The Road with Jim Jones - April 2024
00:31

Let's shed some light on sunscreen!
7:13:56

REdI Annual Conference 2024: CDER (Drugs) Innovation in Medical Product Development (Day 2 of 2)
00:17

Can Cardiac "Organ on a Chip" Technology Help Drug Toxicology Researchers? (Full Video on Channel)
01:06

Dr. Califf on FDA’s Medications for Opioid Use Disorder Campaign: Prescribe with Confidence
9:44:21

June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)
$FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory ped...$ 04:01

FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory ped...
02:04

Opioid Use Disorder, New Biosimilar, Black Family Cancer Awareness Week, & more | In Your Day Ep. 6

Similar videos